FIT Biotech Oy: APPOINTMENTS IN FIT BIOTECH’S MANAGEMENT – FIT Biotech

Reports and Releases

FIT Biotech Oy: APPOINTMENTS IN FIT BIOTECH’S MANAGEMENT

FIT Biotech Oy

Company release April 27, 2017 at 9:00 am EET

APPOINTMENTS IN FIT BIOTECH'S MANAGEMENT

FIT Biotech Oy ("Company") has outsourced financial management and appoints Kaisa Kokkonen as CFO. Ms. Kokkonen, M.Sc. (Economics), HT auditor, is a Principal at Akeba Oy, a financial consulting firm. She has prior experience from financial management and performance enhancement for example from CFO of Talentum Oyj, CFO of VTI Technologies Oy and Director of finance of Hackman Oyj.

The Company has appointed Matti Lähde as Manager of Tampere Operation. Mr. Lähde has been Vice President, Production, at FIT Biotech for the past two years. He has experience in research, process development and biological production. Prior to FIT Biotech he was responsible for the manufacturing of gene therapy products in a cGMP environment of Ark Therapeutics Oy. He also has experience with cancer research from Orion and virology research at Turku University.

Both appointments are temporary during Company's current Senior Vice President, Country Manager and CFO Ms Liisa Laitinen's long leave of absence.

Chairman of the Board Rabbe Slätis comments:
"We are fortunate to have two individuals as eminently qualified as Ms. Kokkonen and Mr. Lähde quickly and seamlessly step into the functions. Ms. Kokkonen and Mr. Lähde will work with the rest of the management team to execute the strategic objectives set out by the board of directors."

FIT BIOTECH OY

Further information:
Rabbe Slätis
Chairman of the Board
FIT Biotech Oy
Tel: +358 40 8406749
E-mail: rabbe.slatis@fitbiotech.com

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

DISTRIBUTION:
Nasdaq Helsinki
Principal media

Back to list